Full Press Release Details
PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA.
ALT
PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA
Key Takeaway: PharmAthene Reports Year-End 2015 Financial and Operational Results; Provides Update on Litigation with SIGA
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight